Who was studied, and how
Two numbers in the abstract
Where each one falls
Where it lands on the map
What it changes
Among 23 other studies
2,341people with cardiovascular disease, in this paper
The trial randomly assignedassigned by chance
alirocumab (150 mg)
placebo
Reported lower percentage change from baseline in calculated LDL cholesterol level, no range given−62.0
randomisedThe trial randomly assignedassigned by chance
alirocumab
placebo
Lowered major heart events−48%
randomisedthe abstract, start to end
… in calculated LDL cholesterol level was -62 percentage points (P<0.001); …
… placebo (1.7% vs. 3.3%; hazard ratio, 0.52; 95% confidence interval, 0.31 …
← favours treatmentfavours comparator →
could be chanceNo interval given · direction only, strength unknown
Mean percentage change from baseline in calculated LDL cholesterol levelalirocumab (150 mg) vs placebo
−62
Major adverse cardiovascular events (death from coronary heart disease, nonfatal myocardial infarction, fatal or nonfatal ischemic stroke, or unstable angina requiring hospitalization)alirocumab vs placebo
HR 0.520.31–0.90
PCSK9 inhibitorsLipidsCardiovascular events
PCSK9 inhibitors × lipidshelps?settled
unlikelylikely
0.930.93 without it
PCSK9 inhibitors × cardiovascular eventshelps?settled
unlikelylikely
1.001.00 without it
← favours treatmentfavours comparator →
1 / 6